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Abstract
Background
Rapid coronary recanalization following ST-elevation myocardial infarction (STEMI)
requires effective anti-platelet and anti-thrombotic therapies. This study tested the impact of
door to end of procedure (‘door-to-end’) time and baseline platelet activity on platelet inhibi-
tion within 24hours post-STEMI.
Methods and Findings
108 patients, treated with prasugrel and procedural bivalirudin, underwent Multiplate1 plate-
let function testing at baseline, 0, 1, 2 and 24hours post-procedure. Major adverse cardiac
events (MACE), bleeding and stent thrombosis (ST) were recorded. Baseline ADP activity
was high (88.3U [71.8–109.0]), procedural time and consequently bivalirudin infusion duration
were short (median door-to-end time 55minutes [40–70] and infusion duration 30minutes
[20–42]). Baseline ADP was observed to influence all subsequent measurements of ADP
activity, whereas door-to-end time only influenced ADP immediately post-procedure. High
residual platelet reactivity (HRPR ADP>46.8U) was observed in 75% of patients immediately
post-procedure and persisted in 24% of patients at 2hours. Five patients suffered in-hospital
MACE (4.6%). Acute ST occurred in 4 patients, all were <120mins post-procedure and had
HRPR. No significant bleeding was observed. In a post-hoc analysis, pre-procedural mor-
phine use was associated with significantly higher ADP activity following intervention.
Conclusions
Baseline platelet function, time to STEMI treatment and opiate use all significantly influence
immediate post-procedural platelet activity.
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Introduction
Optimal treatment of acute ST-elevation myocardial infarction (STEMI) requires early re-
canalisation of the occluded coronary artery by primary percutaneous coronary intervention
(PPCI) and passivation of coronary artery thrombosis with combined antiplatelet and antico-
agulant drugs[1].
Prasugrel provides fast and effective platelet inhibition[2,3], although high baseline platelet
activity, reduced drug bioavailability and concomitant use of opiates in the setting of STEMI
may delay the antiplatelet effect of a loading dose[4,5]. Bivalirudin causes rapid thrombin inhi-
bition and has a low bleeding risk. However, its short half-life is associated with an increased
risk of acute stent thrombosis (ST) when treatment is limited to the peri-procedural period[6].
It was hoped that combined use of bivalirudin with prasugrel, a more potent oral P2Y12
antagonist than clopidogrel, would provide faster and more consistent inhibition of platelet
activity, with improved clinical outcomes, particularly through minimizing the risk of acute ST
[7]. Unfortunately BRAVE-4, a trial designed to test this combination of agents, was stopped
prematurely due to slow recruitment and analysis of the outcomes for the 548 patients enrolled
failed to show superiority of bivalirudin/prasugrel vs heparin/clopidogrel[8].
Acute STEMI pharmacotherapy is challenged by the potential conflict between shortening
the time to revascularization and consequent reduction of exposure of patients to anti-platelet
and anti-thrombotic therapy. PINPOINT-PPCI was designed to address these uncertainties.
We aimed to profile platelet activity during the first 24 hours of treatment for STEMI using
bivalirudin and prasugrel. Recent clinical data has highlighted an increased risk of acute ST in
revascularized target lesions when bivalirudin is used, compared to unfractionated heparin
monotherapy combined with potent oral P2Y12 inhibition[9]. Our study tests the interaction
between procedural timing and acute antiplatelet and antithrombotic therapy, providing
insights into the mechanisms driving acute ST with use of prasugrel and procedural
bivalirudin.
Methods
Study design
The PINPOINT-PPCI study is a single-centre study of patients receiving anti-thrombotic treat-
ment and PPCI for acute STEMI. The study was approved by a UK NHS Research Ethics Com-
mittee Number (REC: 10/H0106/87) on 20th December 2010. The study was registered with
Current Controlled Trials (www.controlled-trials.com/ISRCTN82257414), trial registration
was completed following the commencement of patient recruitment due only to administrative
delays. Patients presenting with acute STEMI between June 2011 & February 2013 were
checked for eligibility and were invited to give verbal assent for participation at the time of
emergency admission; patients were re-approached to give written consent after PPCI, within
24 hours of admission. The study protocol has been reported previously[10].
Study population
Patients were eligible for the study if they presented to our regional heart attack unit with acute
STEMI requiring PPCI. Patients were excluded if they had: active bleeding, or a bleeding diath-
esis; previous history of cerebrovascular event; use of clopidogrel, prasugrel or ticagrelor within
7 days of presentation; or haemodynamic instability.
The study participants received standard care for STEMI at our institution, comprising an
oral loading dose of 300 mg aspirin administered in the community or after admission to hos-
pital plus a loading dose of 60 mg prasugrel as soon as possible after admission in the
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emergency room or cathlab. At the start of PPCI, participants also received a 0.75 mg/kg bolus
of bivalirudin followed by a 1.75 mg/kg/h infusion for the duration of the procedure. Use of
unfractionated heparin was discouraged and participants were withdrawn if their management
required use of a glycoprotein receptor inhibitor or continuation of the bivalirudin infusion
after the PPCI.
Platelet function tests
Venous blood samples for platelet function testing were collected into hirudin vacutainer tubes
(Verum Diagnostica GmbH, Germany) on arrival at hospital, immediately after completion of
the PPCI and 1, 2 and 24 hours post-procedure (Fig 1). At each time point, three platelet func-
tion assays were measured using whole blood electrical impedance aggregometry (Multiplate1
analyzer, Roche Diagnostics International Ltd., Switzerland), namely ADP (ADP-test, Roche
Diagnostics GmbH), arachidonic acid (ASPI-test, Roche Diagnostics GmbH) and thrombin
receptor activating peptide (TRAP; TRAP-test, Roche Diagnostics GmbH). Additionally, the
blood samples collected on arrival at hospital and at 24hours post-PPCI were also analysed to
assess Thromboxane A2 receptor activity, using the synthetic Thromboxane A2 receptor ago-
nist U46619. Platelet responses to test reagents were expressed as the area under the curve
(AUC) of the change in electrical impedance in the first 6 minutes of analysis, presented in
units (U; 1 U corresponds to 10 AUmin).
Study outcomes
The primary outcome was the AUC for the response to the ADP-test. The secondary platelet
function outcomes were the AUCs for the responses to ASPI-test, TRAP-test and U46619.
Fig 1. PINPOINT-PPCI study timeline. LD–loading dose, PFA–platelet function assessment. Times
displayed are medians and IQRs. *The median baseline PFA time was 2 minutes after procedure start (IQR
-1 to 6). **The median residual PFA1 time was 0 minutes post procedure (IQR 0 to 2). Missing data were as
follows: 1 patient was missing flow time; 5 patients were missing baseline PFA times; 4 patients were missing
residual PFA1 times; 8 patients were missing residual PFA2 times; 8 patients were missing residual PFA3
times; 17 patients were missing residual PFA4 times.
doi:10.1371/journal.pone.0144984.g001
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The secondary clinical outcomes were the incidence of major adverse cardiac events
(MACE–a composite of target vessel revascularisation, non-fatal MI, and cardiac death), bleed-
ing complications (using the trials in myocardial infarction (TIMI) major and minor bleeding
criteria[11]) and ST (Academic research consortium (ARC) definition[12]) at 24 hours and 30
days after PPCI.
Additional data collected
For each participant, we recorded the time of onset of symptoms, admission to hospital and
the start and end times of the PPCI procedure. We also recorded the baseline characteristics of
the participants, the time of administration of anti-thrombotic and other drugs, and procedural
characteristics of the PPCI. We recorded data on several potential confounding factors that
affect the characteristics of the index MI and might also have influenced door-to-balloon time
and platelet reactivity on presentation. These were timing of symptoms/presentation relative to
the time of arrival at hospital, age, diabetes, and prior long-term treatment with aspirin.
Statistical methods
There were two key predictors of interest, namely door to end of procedure time and platelet
activity at the time of arrival at hospital (baseline). We made the following assumptions to esti-
mate the target sample size required to detect a statistically significant effect of key predictors
of platelet function in a regression model: r2 = 0.25 for the full model; r2 = 0.2 for the model
excluding the key predictors but with up to eight covariates; correlation of 0.5 between repeated
measures; inclusion of two key predictors of interest in the model. Given these assumptions, a
sample size of 108 was required to detect a gradient different from zero with 80% power and
5% significance (Bonferroni-corrected due to estimating the effects of two predictors).
Continuous data are presented as means and standard deviations (SD), or medians and
interquartile ranges (IQRs) if distributions appear to be skewed. Categorical data are presented
as numbers and percentages.
Analyses followed a pre-specified statistical analysis plan. The primary and secondary plate-
let function outcomes (ADP, ASPI, TRAP and U46619), measured at four time points after
completion of PPCI, were analyzed using linear mixed model regression fitting the two key pre-
dictors and time as fixed effects regardless of significance. The interaction between the two key
predictors was also included if it reached statistical significance at 10%, as were the interactions
between each key predictor and time. A correlated participant-term random effect was
included in each model to allow for repeated measures. In the pre-specified analysis plan, we
decided not to apply any Bonferroni correction in the analyses.
Results are reported as effect estimates with 95% confidence intervals (CI). If the interaction
with time was significant, estimates at each of the four time points are presented; otherwise
estimates that are constant over time are presented. We adjusted for the potential confounding
factors described above as fixed effects if they reached statistical significance at the 5% level.
Model validity was checked using standard graphical methods and transformations were
explored if a model fitted poorly. Outcomes analyzed on the logarithmic scale were trans-
formed back to the original scale after analysis and results presented as geometric mean ratios
(GMR).
The intention in the study protocol was to analyze the secondary safety outcomes (MACE,
bleeding and ST) using logistic regression, with adjustments as stated above. However, due to
insufficient numbers of events they are presented descriptively.
A post-hoc analysis of the platelet activity measurements by whether or not participants
received morphine (or morphine plus anti-emetics) on hospital arrival is also reported,
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prompted by previous studies suggesting an association between opiate use and delayed P2Y12
antagonist platelet inhibition[4,13]. As above, these were analyzed using linear mixed model
regression, with baseline and follow up platelet function as outcomes, and morphine (three-
level categorical variable), time and the interaction between the two fitted as fixed effects. The
interaction was only included if it was statistically significant at the 10% level.
Results
One hundred and eight patients participated in the study. The mean age was 61.1years (SD
11.7) and 86/108 (79.6%) were male. Further characteristics of the participants are presented in
Table 1.
The majority of cases were undertaken via the radial artery (101/108 patients, 93.5%) with
one access site complication (0.9%), involving intense radial spasm requiring a general anes-
thetic to remove the guide catheter. Angiographic procedural success (residual stenosis<20%)
was achieved in 105/107 cases (98.1%) with drug-eluting stents deployed in 56 cases (51.9%).
Further procedural details are outlined in Table 2.
Table 1. Baseline clinical and demographic characteristics.
All patients (n = 108)
DEMOGRAPHICS n %
Gender (male) 86/108 79.6%
Age (years) (mean, SD) 61.1 11.7
BMI (mean, SD) * 27.6 4.5
Heart rate (bpm) (mean, SD) 74.1 18.6
Systolic blood pressure (mean, SD) ** 134.3 28.6
Diastolic blood pressure (mean, SD) ** 81.7 19.8
Smoking status
Non-smoker 31/108 28.7%
Smoker 45/108 41.7%
Ex-smoker 32/108 29.6%
MEDICAL HISTORY n %
Diabetes 15/108 13.9%
Diet/oral controlled 8/108 7.4%
Insulin controlled 7/108 6.5%
Long term aspirin 21/108 19.4%
Family history of heart disease 54/108 50.0%
Peripheral vascular disease 3/108 2.8%
Hypercholesterolaemia 43/108 39.8%
Cerebrovascular disease 2/108 1.9%
Hypertension requiring treatment 38/108 35.2%
History of renal failure or dialysis 1/108 0.9%
Previous MI 7/108 6.5%
Previous PCI 5/108 4.6%
Previous CABG 2/108 1.9%
*1 patient missing data
**4 patients missing data
(CABG coronary artery bypass graft, MI myocardial infarction, PCI percutaneous coronary intervention, SD
standard deviation)
doi:10.1371/journal.pone.0144984.t001
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One hundred and six patients (98.1%) received a 300 mg loading dose of aspirin, the major-
ity (100/106) administered before admission to hospital (median time between aspirin loading
and start of PPCI 61 minutes (IQR 41, 87)). One patient received a 150mg loading dose of aspi-
rin and another received 900 mg. Twenty one participants (19.4%) presented on long term
aspirin therapy. All participants received the loading dose of prasugrel at a median interval of 8
minutes (IQR 3, 20) after admission to hospital. The median duration of bivalirudin infusion
was 30 minutes (IQR 20, 42). Further details of procedural and study timings are outlined in
Fig 1.
Table 2. Angiographic and procedural characteristics.
All patients (n = 108)
PROCEDURAL TIMINGS Median IQR
Onset of symptoms to arrival at BHI (mins) 135 (80.0, 207.5)
Door to end of procedure (mins) 55 (40.0, 70.0)
Total procedure time (mins) 38 (30.0, 51.5)
Call to balloon (flow) time* (mins) 101 (81.0, 123.0)
Door to balloon (flow) time* (mins) 27 (19.0, 40.0)
PROCEDURAL CHARACTERISTICS n %
Morphine on admission
Morphine 36/106 34.0%
Morphine + anti-emetics 44/106 41.5%
No morphine 26/106 24.5%
Bivalirudin infusion duration (mins) (median,
IQR)*
30 (20.0, 42.0)
Unfractionated heparin 0/108 0.0%
GP2b/3a inhibitor used 0/108 0.0%
Radial access 101/108 93.5%
Femoral access § 13/108 12.0%
Thrombectomy* 84/107 78.5%
IABP inserted 1/108 0.9%
Access site complication ‡ 1/108 0.9%
Stent type
BMS 51/108 47.2%
DES 56/108 51.9%
No stent 1/108 0.9%
Culprit vessel
Right coronary artery 53/108 49.1%
Left anterior descending 32/108 29.6%
Circumflex 22/108 20.4%
Left main stem 0/108 0.0%
Vein graft 1/108 0.9%
Procedural success* 105/107 98.1%
* 1 patient missing data
§ 6/13 = Failed radial, 7/13 default femoral
‡ Intense spasm right radial required anaesthetic
(BHI Bristol Heart Institute, BMS bare metal stent, DES drug-eluting stent, GP2b/3a inhibitor Glycoprotein
2b/3a receptor inhibitor, IABP intra-aortic balloon pump, IQR interquartile range)
doi:10.1371/journal.pone.0144984.t002
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Primary outcome
At admission to hospital, the median platelet ADP response was 88.3 U (IQR 71.8, 109.0; the
manufacturer's reference interval for controls not receiving antiplatelet drugs is 57–113 U).
Immediately after completion of PPCI the median ADP response was 75.7 U (IQR 47.2, 90.7),
falling to 38.4 U (IQR 18.8, 68.3) 1 hour after PPCI, 23.4 U (IQR 13.7, 46.5) 2 hours after PPCI
and 14.4 U (IQR 10.3, 20.3) 24 hours after PPCI (Fig 2A). A total of 80/106 (75%) participants
displayed high residual platelet reactivity immediately after PPCI (HRPR; previously defined as
ADP response>46.8 U[14]) indicating incomplete platelet P2Y12 blockade. This number
reduced to 44/103 (43%) 1 hour after PPCI, 25/103 (24%) 2 hours after PPCI and 3/106 (3%)
24 hours after PPCI (Fig 2B).
Baseline ADP activity had a large effect on ADP immediately post intervention; for every
unit increase in ADP response at admission, the ADP response increased on average by 0.45 U
(95% CI 0.29 to 0.62), see Fig 3. The magnitude of this effect reduced substantially over time
but was still apparent 24 hours after PPCI (0.06 U, 95% CI 0.008 to 0.11). Door to end of proce-
dure time had a small but statistically significant effect on ADP immediately post procedure;
for every minute increase in door to end time, ADP decreased by 0.25 U (95% CI -0.46 to
-0.04), on average. This effect did not persist for the other three time points (Fig 3).
Secondary outcomes
The median ASPI-test platelet response was 27.9 U (IQR 20.3, 53.2) at admission (manufac-
turer's reference interval for controls not receiving antiplatelet drugs 71–115 U) falling slowly
and consistently over the subsequent time points to a median of 7.3 U (IQR 3.2, 13.0) at 24
hours post-PPCI. The platelet TRAP-test and U44619 responses showed similar kinetics (S2
Fig).
As baseline ASPI increased, post intervention ASPI on average increased, with this effect
reducing in magnitude over time (immediately post procedure estimate 0.65, 95% CI 0.54 to
Fig 2. ADP platelet reactivity profile. Panel A—Median ADP receptor platelet activity profile in first 24 hours
post-presentation with STEMI and treatment with PPCI. Red markers identify platelet response for the four
acute ST patients (dotted line indicates the high residual platelet reactivity threshold of 46.8 U for ADP-test).
Panel B–The profile of high residual platelet activity, in the first 24 hours, following administration of a 60 mg
Prasugrel loading dose at the time of PPCI.
doi:10.1371/journal.pone.0144984.g002
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0.75, 24 hours post procedure estimate 0.06, 95% CI 0.02 to 0.10). Similarly, as baseline TRAP
increased, post procedure TRAP on average increased; this effect persisted at all four time
points. U44619 activity was only measured at baseline and 24hours post procedure. Results are
presented as GMRs because the data were transformed. Baseline U44619 had a small but statis-
tically significant effect on 24hour U44619 such that for every 10unit increase in baseline
U44619, 24hour U44619 was on average 2.5% higher. Door to procedure end time had no
effect at any time point after PPCI for the secondary outcomes ASPI-test, TRAP-test and
U44619 (S3 Fig).
There were no associations of patient age, presence of diabetes, interval between the onset of
symptoms and admission and previous longterm aspirin treatment with the platelet responses
at the end of PPCI (data not shown).
Adverse events / safety
During the 30 day follow-up period, five patients (4.6%) experienced MACE; four were acute
ST and one was a sub-acute ST, all resulting in target vessel re-infarction and re-intervention.
All four acute STs occurred within 2 hours of completion of procedure. Intravascular imaging
confirmed that there had been a procedural complication in 2 of the 4 events (malapposition
and distal stent edge disruption). The sub-acute ST occurred 18 days after the index PPCI, 5
days after stopping prasugrel in anticipation of coronary arterial bypass grafting for severe
bystander disease. No significant bleeding was observed. Further to these pre-specified safety
outcomes, there were 11 serious adverse events reported in nine patients. Two were during ini-
tial hospital stay and resulted in prolonged stay, and nine were after initial hospital discharge
and resulted in readmissions. No patients died during the 30 day follow-up period. See S1
Table for details.
Fig 3. Effect of door to end of procedure time and baseline ADP platelet activity on ADP platelet
function in the first 24 hours post-presentation with STEMI and treatment with PPCI.
doi:10.1371/journal.pone.0144984.g003
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Post-hoc analyses
The influence of baseline morphine use on platelet activity was investigated in post-hoc analyses
for all four platelet measures; 36/106 (34.0%) patients received morphine alone, 44/106 (41.5%)
received morphine plus anti-emetics and 26/106(24.5%) patients received no morphine. The
effect of morphine on ADP significantly differed across the five time points (morphine group by
time interaction p<0.001). The strongest effect was observed at the end of PPCI (p<0.001);
patients who received morphine before the procedure had higher levels of ADP (median 90.1 U,
IQR 66.8–110.8, n = 35) compared to those who received morphine plus anti-emetics (median
75.9 U, IQR 61.1–89.4, n = 44) or those who did not receive morphine (median 43.5 U, IQR
19.3–72.1, n = 25). A significant morphine effect was also observed at 1 and 2 hours post-PPCI
(p = 0.035 and p = 0.007, respectively); no morphine effect was observed at baseline or 24 hours
post-PPCI (p = 0.56 and p = 0.16, respectively). Morphine was found to influence TRAP with
borderline statistical significance (p = 0.08), although there was no evidence that this effect dif-
fered over time (morphine group by time interaction p = 0.30). No clear pattern was seen when
investigating the effect of morphine on ASPI and U44619 (Fig 4).
Discussion
This study describes the largest cohort of STEMI patients, treated acutely with prasugrel and
bivalirudin, undergoing detailed platelet function profiling in the first 24 hours of treatment.
We have demonstrated significant heterogeneity of baseline platelet activity. We have con-
firmed a relationship between baseline ADP activity and the post-procedural ADP activity
measurements, following acute loading of prasugrel and a peri-procedural bivalirudin infusion.
Fig 4. Influence of pre-procedural opiate and anti-emetic treatment on platelet function in the first 24
hours post-presentation with STEMI and treatment with PPCI. ADP: morphine effects pre-PPCI p = 0.56,
end of PPCI p<0.001, 1 hour post-PPCI p = 0.035, 2 hours post-PPCI p = 0.007, 24hours post-PPCI p = 0.16;
morphine x time interaction p<0.001. ASPI: morphine effect p = 0.67; morphine x time interaction p = 0.36.
TRAP: morphine effect p = 0.08; morphine x time interaction p = 0.30. U44619: morphine effect p = 0.43;
morphine x time interaction p = 0.82.
doi:10.1371/journal.pone.0144984.g004
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The same relationship was observed with assessment of thrombin receptor and arachidonic
acid pathway platelet function.
A short door to end of procedure time resulted in a reduced immediate post-procedural effi-
cacy of P2Y12 inhibition. However, we observed effective aspirin-related platelet inhibition in
more than 75% of patients at the end of procedure, reflecting pre-hospital administration of
the drug by ambulance staff and the excellent bioavailability of aspirin. In contrast, and consis-
tent with previously published data[4,15], we observed relatively ineffective inhibition of the
ADP receptor function by prasugrel, as judged by the proportion of patients with HRPR; 75%
patients had HRPR at the end of procedure (53 minutes post-prasugrel LD), falling to 24% 2
hours post-procedure (176 minutes post-prasugrel LD). This differs markedly from the phar-
macokinetic data achieved in healthy volunteers and stable patients but is unsurprising in view
of the high baseline platelet activity and the rapid transit of patients through the cathlab
(median prasugrel to procedure start time 8 minutes and median procedure time 38 minutes).
The use of a double loading dose has been shown to enhance platelet inhibition with a signifi-
cant reduction in patients with HRPR at 2 hours[16]. Alternative strategies to enhance platelet
inhibition have been tested with other anti-platelet agents, including: pre-hospital drug admin-
istration[17], crushing of tablets[18] and use of an intravenous P2Y12 receptor inhibitor[19].
Large-scale clinical trials have highlighted a potential risk of acute ST relating to the abrupt
cessation of bivalirudin at the end of the PPCI procedure[6,9]. Our study used the same proto-
col of bivalirudin administration and we observed a high rate of acute ST (3.7%), all occurring
within the first 2 hours post-procedure. It would seem likely that the HRPR observed within
our study cohort, combined with the rapid reversal of the effect of bivalirudin following cessa-
tion of the drug (half-life approximately 25minutes[20]) conspire to heighten the risk of acute
ST.
In lower risk cohorts, multiplate platelet function testing has successfully been used to iden-
tify patients at risk of ST[21]. Similarly, adverse events have been associated with HRPR
detected in ACS patients loaded with prasugrel[15]. However, subsequent large multicentre tri-
als attempting to ‘tailor’ therapy with adjustment of antiplatelet therapy according to HRPR
have failed to demonstrate benefit[22–25]. Our intensive profiling of platelet function during
the first 24 hours of treatment for STEMI offers potential insights into the aetiology of early
adverse events. Acute ST was observed within 1–2 hours of the procedure (cessation of bivalir-
udin). However, it does not appear that the baseline or immediate post-procedural platelet
function test could be used to predict ST or facilitate individualized therapy. The baseline ADP
platelet activity in the 4 patients suffering acute ST was well distributed (Fig 2), and 75% of the
entire cohort failed to achieve effective ADP inhibition at the time of stopping bivalirudin.
Post-hoc analysis of our data supports the existence of a relationship between opiate use
and impaired platelet inhibition[4]. Pooled data from a series of STEMI trials involving platelet
function assessment (predominantly VerifyNow)[26] have confirmed the association between
opiate use and delayed platelet inhibition following ticagrelor or prasugrel loading, even when
adjusting for vomiting. Our use of multiplate platelet function analysis extends the understand-
ing of this relationship, through simultaneous assessment of platelet ADP, arachidonic path-
way, and thrombin receptor function. Baseline ADP activity did not appear to be influenced by
the administration of opiates (Fig 4). However, at subsequent time points, we observed delayed
ADP platelet inhibition in the presence of opiate, with some reduction of the effect when an
anti-emetic was co-administered. This finding strengthens the hypothesis that the opiate effect
on platelet function relates to a combination of increased vomiting and reduced drug absorp-
tion with a less potent oral P2Y12 inhibitor, clopidogrel[13]. Interestingly, ASPI platelet func-
tion was unaffected by opiate administration. In the majority, aspirin was co-administered
with the opiate by a paramedic (aspirin loading occurred 61minutes (IQR 41 to 88) before
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commencement of PPCI) and the excellent bioavailability of the drug is likely to have facili-
tated effective platelet inhibition. Similarly, no difference in TRAP activity was observed
between patients receiving opiate and those naïve of the drug.
Study Limitations
Several important limitations to the study design merit discussion. Most important was the
need to exclude patients requiring additional treatment with anti-thrombotic/glycoprotein
inhibitor therapy. This exclusion is the reason for the low MACE and bleeding rates observed
but does not change the observations about platelet function among the eligible participants.
Additionally, the requirement for platelet function assessment at multiple time points limited
recruitment to periods when research staff were available to undertake analysis. Consequently,
there was a selection bias to patients presenting during working hours but we know of no rea-
son why the findings should vary by time of presentation.
Despite a number of patients experiencing acute ST, a full platelet profile across all 5 time-
points was not possible for these patients due to the need for emergency intervention and the
subsequent use of intravenous glycoprotein antagonists. Additionally, the study was under-
taken in a single centre and the relatively small sample size limited the interpretation of
observed clinical endpoints.
The interaction between the increasing platelet inhibition following administration of a pre-
procedural prasugrel loading dose and the waning anti-thrombotic effect of bivalirudin, follow-
ing cessation of the infusion, at the end of the PPCI procedure, is likely to contribute to the
occurrence of acute ST. Unfortunately, despite a measurable effect of bivalirudin on platelet
aggregation using Multiplate[27], our analysis is unable to distinguish between the effects of
the two drugs administered during the acute intervention.
Parameters of interest were fitted in multiple regression models and, when drafting the anal-
ysis plan, we judged that a Bonferroni correction would be too conservative. We acknowledge
that multiplicity of comparisons may be an issue but, nevertheless, pre-specified that we would
not adjust p-values. Consistency of findings is an important consideration when judging cau-
sality[28] and we have no information on which to base an adjustment or choice of a criterion
for assigning significance that would be less conservative than Bonferroni. In these circum-
stances, we believe that (a) we should not depart from our analysis plan and (b) applying one
or other method would represent an arbitrary decision, which would not aid interpretation of
the findings.
Conclusions
The acute nature of STEMI presentation, requiring immediate invasive intervention, combined
with high baseline platelet activity and a tendency to thrombosis poses major challenges. The
balance of thrombosis and bleeding is delicate. We have confirmed significant variability in
baseline platelet ADP function with a persisting effect on ADP activity in the first 24 hours,
despite early oral antiplatelet administration. The pursuit of rapid mechanical recanalization of
the occluded artery further impacts on immediate post-procedural ADP receptor inhibition,
with a persisting high rate (24.3%) of HRPR 2 hours following PPCI. Additionally, administra-
tion of opiates in the acute setting appears to further delay inhibition of platelet ADP activity.
The combination of prasugrel and bivalirudin provides an excellent safety profile, with regards
to bleeding, but is associated with a high rate of acute ST, if bivalirudin is stopped at the end of
the procedure.
An optimal pharmacological strategy for PPCI is yet to be found but our data supports fur-
ther evaluation of methods to accelerate platelet inhibition or prolong thrombin inhibition.
Platelet Inhibition during Acute Treatment for STEMI
PLOS ONE | DOI:10.1371/journal.pone.0144984 December 16, 2015 11 / 14
Supporting Information
S1 STROBE Checklist.
(DOCX)
S1 Fig. Consort flow diagram.
(DOCX)
S2 Fig. The median platelet activity profiles in the first 24hours post-PPCI.Median platelet
activity profiles for arachidonic acid pathway (ASPI–Panel A), thrombin receptor (TRAP–
Panel B) and thromboxane A2 receptor (U44619 –Panel C) function in the first 24 hours post-
presentation with STEMI and treatment with PPCI. Red markers identify platelet response for
the four acute ST patients (dotted line indicates the high residual platelet reactivity threshold of
40 U for ASPItest)
(TIF)
S3 Fig. The effect of door to end of procedure time and baseline platelet activity on second-
ary outcome measures. Effect of door to end of procedure time and baseline platelet activity
on arachidonic acid pathway (ASPI–Panel A), thrombin receptor (TRAP–Panel B) and throm-
boxane A2 receptor (U44619 –Panel C) platelet function in the first 24 hours post-presentation
with ST-elevation myocardial infarction and treatment with primary percutaneous coronary
intervention (PPCI). ASPI: door to end time x time interaction p = 0.394, ASPI baseline x time
interaction p<0.01. TRAP: door to end time x time interaction p = 0.394, TRAP baseline x
time interaction p = 0.083. U44619: Only collected at baseline and 24 hours post-PPCI.
(TIF)
S1 Table. Serious Adverse Events.
(DOCX)
S1 Text. PINPOINT-PPCI Trial Protocol.
(DOC)
Acknowledgments
We thank all the staff working in the cardiac catheterisation laboratories and CCU at Bristol
Heart Institute for their commitment to this study. We thank Dr Raveen Kandan, the Clinical
Trials Evaluation Unit team and particularly Ruth Bowles, Jon Evans and Debbie Marsden for
their dedication in patient recruitment.
Author Contributions
Conceived and designed the experiments: TWJ ADM SMMB BCR AB. Performed the experi-
ments: TWJ MB JWS AB. Analyzed the data: TWJ ADM LJS SMMB JWS CAR BCR AB. Con-
tributed reagents/materials/analysis tools: TWJ ADM LJS SMMB JWS CAR BCR AB. Wrote
the paper: TWJ ADM LJS SMMB JWS CAR BCR AB.
References
1. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. (2012) ESC Guidelines for the
management of acute myocardial infarction in patients presenting with ST-segment elevation. Euro-
pean heart journal 33: 2569–2619. doi: 10.1093/eurheartj/ehs215 PMID: 22922416
2. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, et al. (2007) A comparison of prasugrel
and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active
metabolite formation. Am Heart J 153: 66 e69-16.
Platelet Inhibition during Acute Treatment for STEMI
PLOS ONE | DOI:10.1371/journal.pone.0144984 December 16, 2015 12 / 14
3. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, et al. (2006) Prasugrel achieves greater inhi-
bition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-
treated patients with stable coronary artery disease. Eur Heart J 27: 1166–1173. PMID: 16621870
4. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, et al. (2013) Comparison of prasugrel and tica-
grelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of
Platelet Inhibitor Drugs) primary PCI study. Journal of the American College of Cardiology 61: 1601–
1606. doi: 10.1016/j.jacc.2013.01.024 PMID: 23500251
5. Heestermans AA, vanWerkum JW, Taubert D, Seesing TH, von Beckerath N, et al. (2008) Impaired
bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res
122: 776–781. doi: 10.1016/j.thromres.2008.01.021 PMID: 18455217
6. Stone GW,Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. (2008) Bivalirudin during Pri-
mary PCI in Acute Myocardial Infarction. N Engl J Med 358: 2218–2230. doi: 10.1056/
NEJMoa0708191 PMID: 18499566
7. Schulz S, Richardt G, Laugwitz KL, Mehran R, Gershlick AH, et al. (2014) Comparison of prasugrel and
bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction:
Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. Clin Cardiol
37: 270–276. doi: 10.1002/clc.22268 PMID: 24633823
8. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, et al. (2014) Prasugrel plus bivalirudin vs.
clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 35:
2285–2294. doi: 10.1093/eurheartj/ehu182 PMID: 24816809
9. Shahzad A, Kemp I, Mars C, Wilson K, RoomeC, et al. (2014) Unfractionated heparin versus bivalirudin
in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised
controlled trial. The Lancet 384: 1849–1858.
10. Johnson TW, Marsden D, Mumford A, Pike K, Mundell S, et al. (2014) Point of care platelet activity
measurement in primary PCI [PINPOINT-PPCI]: a protocol paper. BMC Cardiovasc Disorders 14:
1471–2261.
11. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, et al. (1988) Thrombolysis in Myocardial Infarction (TIMI)
Trial—Phase 1: Haemorrhagic Manifestations and changes in plasma fibrinogen and the fibrinolytic
system in patients treated with recombinant tissue plasminogen activator and streptokinase. JACC 11:
1–11. PMID: 3121710
12. Mauri L, HsiehW-h, Massaro JM, Ho KKL, D'Agostino R, et al. (2007) Stent Thrombosis in Randomized
Clinical Trials of Drug-Eluting Stents. N Engl J Med 356: 1020–1029. PMID: 17296821
13. Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, et al. (2014) Morphine decreases clopi-
dogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Car-
diol 63: 630–635. doi: 10.1016/j.jacc.2013.10.068 PMID: 24315907
14. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, et al. (2009) Platelet Reactivity After Clopidogrel Treat-
ment AssessedWith Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. Journal of the
American College of Cardiology 53: 849–856. doi: 10.1016/j.jacc.2008.11.030 PMID: 19264241
15. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, et al. (2011) High on-treatment platelet reactivity
after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in
acute coronary syndromes. J Am Coll Cardiol 58: 467–473. doi: 10.1016/j.jacc.2011.04.017 PMID:
21777742
16. Alexopoulos D, Makris G, Xanthopoulou I, Patsilinakos S, Deftereos S, et al. (2014) Onset of antiplate-
let action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-seg-
ment-elevation myocardial infarction undergoing primary percutaneous coronary intervention:
pharmacodynamic study. Circ Cardiovasc Interv 7: 233–239. doi: 10.1161/CIRCINTERVENTIONS.
113.001118 PMID: 24668226
17. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, et al. (2014) Prehospital ticagrelor in
ST-segment elevation myocardial infarction. N Engl J Med 371: 1016–1027. doi: 10.1056/
NEJMoa1407024 PMID: 25175921
18. Parodi G, Xanthopoulou I, Bellandi B, Valenti R, Gkizas V, et al. (2014) Ticagrelor crushed tablets
administration in STEMI patients: The Mashed Or Just Integral Tablets of ticagrelOr (MOJITO) study.
European Heart Journal 35(suppl): 1030.
19. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, et al. (2013) Effect of platelet inhibition with
cangrelor during PCI on ischemic events. N Engl J Med 368: 1303–1313. doi: 10.1056/
NEJMoa1300815 PMID: 23473369
20. Robson R (2000) The use of bivalirudin in patients with renal impairment. J Invasive Cardiol: 1042–
3931.
Platelet Inhibition during Acute Treatment for STEMI
PLOS ONE | DOI:10.1371/journal.pone.0144984 December 16, 2015 13 / 14
21. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, et al. (2009) Platelet reactivity after clopidogrel treat-
ment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol
53: 849–856. doi: 10.1016/j.jacc.2008.11.030 PMID: 19264241
22. Price MJ, Berger PB, Teirstein PS, Tanguay J- F, Angiolillo DJ, et al. (2011) Standard- vs High-Dose
Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA: The
Journal of the American Medical Association 305: 1097–1105. doi: 10.1001/jama.2011.290 PMID:
21406646
23. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, et al. (2012) A randomized trial of prasugrel
versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous cor-
onary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Plate-
let Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative
TherapyWith Prasugrel) study. J Am Coll Cardiol 59: 2159–2164. doi: 10.1016/j.jacc.2012.02.026
PMID: 22520250
24. Montalescot G, Range G, Silvain J, Bonnet JL, Boueri Z, et al. (2014) High on-treatment platelet reactiv-
ity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis
of the ARCTIC study. Circulation 129: 2136–2143. doi: 10.1161/CIRCULATIONAHA.113.007524
PMID: 24718568
25. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, et al. (2012) Bedside monitoring to adjust antiplate-
let therapy for coronary stenting. N Engl J Med 367: 2100–2109. doi: 10.1056/NEJMoa1209979 PMID:
23121439
26. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, et al. (2015) Morphine Is Associ-
atedWith a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial
Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 8.
27. Sibbing D, Busch G, Braun S, Jawansky S, SchÃ¶mig A, et al. (2008) Impact of bivalirudin or unfractio-
nated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elec-
tive percutaneous coronary intervention. European Heart Journal 29: 1504–1509. doi: 10.1093/
eurheartj/ehn195 PMID: 18467322
28. Schulz KF, Grimes DA (2005) Multiplicity in randomised trials I: endpoints and treatments. Lancet 365:
1591–1595. PMID: 15866314
Platelet Inhibition during Acute Treatment for STEMI
PLOS ONE | DOI:10.1371/journal.pone.0144984 December 16, 2015 14 / 14
